{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:58:38Z","timestamp":1790812718000,"version":"4.1.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12916-015-0543-9","type":"journal-article","created":{"date-parts":[[2015,12,22]],"date-time":"2015-12-22T09:51:28Z","timestamp":1450777888000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trials"],"prefix":"10.1186","volume":"13","author":[{"given":"Robert J.","family":"van Soest","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,22]]},"reference":[{"issue":"15","key":"543_CR1","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513\u201320.","journal-title":"N Engl J Med"},{"issue":"15","key":"543_CR2","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502\u201312.","journal-title":"N Engl J Med"},{"issue":"2","key":"543_CR3","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","volume":"26","author":"DR Berthold","year":"2008","unstructured":"Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242\u20135.","journal-title":"J Clin Oncol"},{"issue":"4","key":"543_CR4","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.eururo.2014.01.018","volume":"66","author":"MT Schweizer","year":"2014","unstructured":"Schweizer MT, Zhou XC, Wang H, Bassi S, Carducci MA, Eisenberger MA, et al. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Eur Urol. 2014;66(4):646\u201352.","journal-title":"Eur Urol"},{"issue":"6","key":"543_CR5","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.eururo.2014.11.033","volume":"67","author":"RJ Soest van","year":"2015","unstructured":"van Soest RJ, de Morree ES, Kweldam CF, de Ridder CM, Wiemer EA, Mathijssen RH, et al. Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancer. Eur Urol. 2015;67(6):981\u20135.","journal-title":"Eur Urol"},{"issue":"18","key":"543_CR6","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1016\/j.ejca.2013.09.026","volume":"49","author":"RJ Soest van","year":"2013","unstructured":"van Soest RJ, van Royen ME, de Morree ES, Moll JM, Teubel W, Wiemer EA, et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer. 2013;49(18):3821\u201330.","journal-title":"Eur J Cancer"},{"issue":"8","key":"543_CR7","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737\u201346.","journal-title":"N Engl J Med"},{"key":"543_CR8","doi-asserted-by":"publisher","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley D, Spears MR, et al. Adding docetaxel and\/or zoledronic acid for hormone-naive prostate cancer (STAMPEDE): survival results form an adaptive multi-arm multi-stage platform randomised controlled trial. Lancet. 2015, in press. doi: 10.1016\/S0140-6736","DOI":"10.1016\/S0140-6736"},{"key":"543_CR9","doi-asserted-by":"crossref","unstructured":"Vale CL, Burdett S, Rydzewska LHM, Albiges L, Clarke NW, Fisher D, et al. Adding docetaxel or bisphosphonates to standard-of-care in men with localised or metastatic hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. In Press 2015.","DOI":"10.1016\/S1470-2045(15)00489-1"},{"issue":"30","key":"543_CR10","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1200\/JCO.2010.30.7025","volume":"28","author":"RM Franke","year":"2010","unstructured":"Franke RM, Carducci MA, Rudek MA, Baker SD, Sparreboom A. Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol. 2010;28(30):4562\u20137.","journal-title":"J Clin Oncol"},{"issue":"11","key":"543_CR11","doi-asserted-by":"publisher","first-page":"494.e15","DOI":"10.1016\/j.urolonc.2015.06.022","volume":"33","author":"P Kongsted","year":"2015","unstructured":"Kongsted P, Svane IM, Lindberg H, Daugaard G, Sengelov L. Low-dose prednisolone in first-line docetaxel for patients with metastatic castration-resistant prostate cancer: Is there a clinical benefit? Urol Oncol. 2015;33(11):494.e15\u201320.","journal-title":"Urol Oncol"},{"issue":"3","key":"543_CR12","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/S1470-2045(15)70027-6","volume":"16","author":"F Saad","year":"2015","unstructured":"Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, et al. ELM-PC 4 investigators. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncol. 2015;16(3):338\u201348.","journal-title":"Lancet Oncol"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-015-0543-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12916-015-0543-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-015-0543-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T20:51:22Z","timestamp":1567457482000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-015-0543-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["543"],"URL":"https:\/\/doi.org\/10.1186\/s12916-015-0543-9","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]},"article-number":"304"}}